These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 15602166)

  • 21. A multi-country economic evaluation of low-dose aspirin in the primary prevention of cardiovascular disease.
    Lamotte M; Annemans L; Evers T; Kubin M
    Pharmacoeconomics; 2006; 24(2):155-69. PubMed ID: 16460136
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Economic Analysis and Budget Impact of Tenofovir and Entecavir in the First-Line Treatment of Hepatitis B Virus in Italy.
    Ruggeri M; Basile M; Coretti S; Drago C; Cicchetti A
    Appl Health Econ Health Policy; 2017 Aug; 15(4):479-490. PubMed ID: 28197805
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Economic analysis between entecavir and lamivudine for the treatment of chronic hepatitis B in Hong Kong.
    Lee KK; Wu DB; Chow PY; Lee VW; Li H
    J Gastroenterol Hepatol; 2012 Jul; 27(7):1167-74. PubMed ID: 22141402
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Social/economic costs and health-related quality of life in patients with scleroderma in Europe.
    López-Bastida J; Linertová R; Oliva-Moreno J; Serrano-Aguilar P; Posada-de-la-Paz M; Kanavos P; Taruscio D; Schieppati A; Iskrov G; Péntek M; Delgado C; von der Schulenburg JM; Persson U; Chevreul K; Fattore G;
    Eur J Health Econ; 2016 Apr; 17 Suppl 1():109-17. PubMed ID: 27038626
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost of poor adherence to anti-hypertensive therapy in five European countries.
    Mennini FS; Marcellusi A; von der Schulenburg JM; Gray A; Levy P; Sciattella P; Soro M; Staffiero G; Zeidler J; Maggioni A; Schmieder RE
    Eur J Health Econ; 2015 Jan; 16(1):65-72. PubMed ID: 24390212
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Social/economic costs and health-related quality of life in patients with Prader-Willi syndrome in Europe.
    López-Bastida J; Linertová R; Oliva-Moreno J; Posada-de-la-Paz M; Serrano-Aguilar P; Kanavos P; Taruscio D; Schieppati A; Iskrov G; Baji P; Delgado C; von der Schulenburg JM; Persson U; Chevreul K; Fattore G;
    Eur J Health Econ; 2016 Apr; 17 Suppl 1():99-108. PubMed ID: 27038627
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Establishing the health and economic impact of influenza vaccination within the European Union 25 countries.
    Ryan J; Zoellner Y; Gradl B; Palache B; Medema J
    Vaccine; 2006 Nov; 24(47-48):6812-22. PubMed ID: 17034909
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Direct and indirect costs associated with respiratory allergic diseases in Italy. A probabilistic cost of illness study].
    Marcellusi A; Viti R; Incorvaia C; Mennini FS
    Recenti Prog Med; 2015 Oct; 106(10):517-27. PubMed ID: 26442978
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The annual cost of dry eye syndrome in France, Germany, Italy, Spain, Sweden and the United Kingdom among patients managed by ophthalmologists.
    Clegg JP; Guest JF; Lehman A; Smith AF
    Ophthalmic Epidemiol; 2006 Aug; 13(4):263-74. PubMed ID: 16877285
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Medical and economic burden of chronic hepatitis B patients at Queen Savang Vadhana Memorial Hospital.
    Yeekian C; Geratikornsupak N; Chumpongthong P; Tongsiri S; Dhitavat J; Phonrat B; Pitisuttithum P
    J Med Assoc Thai; 2014 Apr; 97(4):447-55. PubMed ID: 24964688
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Population health impact and cost-effectiveness of monitoring inactive chronic hepatitis B and treating eligible patients in Shanghai, China.
    Toy M; Salomon JA; Jiang H; Gui H; Wang H; Wang J; Richardus JH; Xie Q
    Hepatology; 2014 Jul; 60(1):46-55. PubMed ID: 24990105
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The cost-effectiveness of influenza vaccination for people aged 50 to 64 years: an international model.
    Aballéa S; Chancellor J; Martin M; Wutzler P; Carrat F; Gasparini R; Toniolo-Neto J; Drummond M; Weinstein M
    Value Health; 2007; 10(2):98-116. PubMed ID: 17391419
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Individualized treatment of HBeAg-negative chronic hepatitis B using pegylated interferon-α2a as first-line and week-12 HBV DNA/HBsAg stopping rule: a cost-effectiveness analysis.
    Iannazzo S; Coco B; Brunetto MR; Rossetti F; Caputo A; Latour A; Espinos B; Bonino F
    Antivir Ther; 2013; 18(4):623-33. PubMed ID: 23486701
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inpatient Cost Burdens of Treating Chronic Hepatitis B in US Hospitals: A Weighted Analysis of a National Database.
    Lee DU; Bhowmick K; Kolachana S; Schuster K; Bahadur A; Harmacinski A; Schellhammer S; Fan GH; Lee KJ; Sun C; Chou H; Lominadze Z
    Dig Dis Sci; 2024 Jul; 69(7):2401-2429. PubMed ID: 38658506
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Cost of Psoriasis and Psoriatic Arthritis in 5 European Countries: A Systematic Review.
    Burgos-Pol R; Martínez-Sesmero JM; Ventura-Cerdá JM; Elías I; Caloto MT; Casado MÁ
    Actas Dermosifiliogr; 2016 Sep; 107(7):577-90. PubMed ID: 27316590
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe.
    Younossi ZM; Blissett D; Blissett R; Henry L; Stepanova M; Younossi Y; Racila A; Hunt S; Beckerman R
    Hepatology; 2016 Nov; 64(5):1577-1586. PubMed ID: 27543837
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Review of the cost of diabetes complications in Australia, Canada, France, Germany, Italy and Spain.
    Ray JA; Valentine WJ; Secnik K; Oglesby AK; Cordony A; Gordois A; Davey P; Palmer AJ
    Curr Med Res Opin; 2005 Oct; 21(10):1617-29. PubMed ID: 16238902
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of surgical site infection on healthcare costs and patient outcomes: a systematic review in six European countries.
    Badia JM; Casey AL; Petrosillo N; Hudson PM; Mitchell SA; Crosby C
    J Hosp Infect; 2017 May; 96(1):1-15. PubMed ID: 28410761
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chronic venous insufficiency: the effects of health-care reforms on the cost of treatment and hospitalisation--an Italian perspective.
    Allegra C
    Curr Med Res Opin; 2003; 19(8):761-9. PubMed ID: 14687448
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A survey of chronic hepatitis B patient management practices in the European Union.
    Berg T; Benhamou Y; Calleja JL; Levrero M; Johnson W; Ellis N
    J Viral Hepat; 2010 Sep; 17(9):624-30. PubMed ID: 20487257
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.